This study constitutes Phase I of the Registry Program. The main objective of this study is to characterize the newly diagnosed non-valvular AF patient population at risk for stroke and the selection of antithrombotic treatment for stroke prevention in a real-world setting before dabigatran etexilate is approved for the prevention of strokes and systemic emboli in patients with non-valvular AF in different regions of the world.
Study Design: cross-sectional
Study Type
OBSERVATIONAL
Enrollment
1,096
CHADS2 Score
CHADS2 score is based on a point system in which 2 points are assigned for a history of stroke or transient ischemic attack and 1 point each is assigned for age equal to or greater more than 75 years, hypertension, diabetes, or clinical heart failure or impaired left ventricular systolic function (generally interpreted as an ejection fraction ≤ 40%).
Time frame: Baseline
CHA2DS2-VASc Score
The CHA2DS2-VASc risk score is based on a point system in which 2 points are assigned for a history of stroke or TIA, or age ≥75; and 1 point each is assigned for age 65-74 years, a hypertension, diabetes, cardiac failure, vascular disease and female sex. On the basis of the risk strata defined in previous guidelines, a CHA2DS2-VASc score of 0 corresponds to "low risk", a score of 1 corresponds to "intermediate risk", and a score of 2 or more corresponds to "high risk".
Time frame: Baseline
HAS-BLED Risk Score
The HAS-BLED score is based on a point system in which 1 point is assigned for hypertension (systolic blood pressure \>160 mmHg), 1 point for each of abnormal renal (presence of chronic dialysis or renal transplantation or serum creatinine ≥200 μmol/L) and liver (chronic hepatic disease or biochemical evidence of significant hepatic derangement) function, 1 point each is assigned for stroke, bleeding (previous bleeding history and/or predisposition to bleeding), labile Internation Normalized Ratios (INRs,unstable/high INRs or poor time in therapeutic range), age \>65 years and 1 point each for drugs (such as antiplatelet agents, non-steroidal anti-inflammatory drugs) or alcohol.
Time frame: Baseline
Antithrombotic Treatment Choice at Baseline
Time frame: Baseline
Gender
Time frame: Baseline
Age Group
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
1160.114.08017 Boehringer Ingelheim Investigational Site
Beijing, China
1160.114.08018 Boehringer Ingelheim Investigational Site
Beijing, China
1160.114.08019 Boehringer Ingelheim Investigational Site
Beijing, China
1160.114.08020 Boehringer Ingelheim Investigational Site
Beijing, China
1160.114.08023 Boehringer Ingelheim Investigational Site
Beijing, China
1160.114.08024 Boehringer Ingelheim Investigational Site
Beijing, China
1160.114.08025 Boehringer Ingelheim Investigational Site
Beijing, China
1160.114.08007 Boehringer Ingelheim Investigational Site
Changsha, China
1160.114.08021 Boehringer Ingelheim Investigational Site
Dalian, China
1160.114.08004 Boehringer Ingelheim Investigational Site
Ghuangzhou, China
...and 52 more locations
Medical History
Time frame: Baseline
Concomitant Medication
Time frame: Baseline